Cash balances and operating cash flow are influenced by the timing and level of payments by the Company's licensees and development partners, as well as by the Company's net income. We are making important progress in each of these programs. XOMA and Genentech, Inc. are jointly developing this humanized monoclonal antibody that selectively inhibits immune system T cells. Enrollment is now complete in the first of these trials. An article about the results of the Phase III study in patients with severe meningococcemia has been submitted for publication in a peer-reviewed medical journal.
Additional indications are under review.
The present arrangement includes all products containing rBPI to treat any eye infection. Preclinical and formulation work is in progress. The Company is in discussions with potential partners regarding developing products to treat eye diseases, such as diabetic retinopathy. This assay was developed with XOMA's patented technology that uses LBP as a biochemical marker of systemic exposure to gram-negative bacteria and endotoxin. To listen to the live call, please go to the Web site at least 15 minutes prior to the start of the call to register, download and install any necessary audio software.